Cargando…
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
BACKGROUND: Therapeutic options are limited in secondary progressive multiple sclerosis (SPMS). Open-label studies suggested efficacy of monthly IV cyclophosphamide (CPM) without induction for delaying progression but no randomized trial was conducted so far. OBJECTIVE: To compare CPM to methylpredn...
Autores principales: | Brochet, Bruno, Deloire, Mathilde S. A., Perez, Paul, Loock, Timothé, Baschet, Louise, Debouverie, Marc, Pittion, Sophie, Ouallet, Jean-Christophe, Clavelou, Pierre, de Sèze, Jérôme, Collongues, Nicolas, Vermersch, Patrick, Zéphir, Hélène, Castelnovo, Giovanni, Labauge, Pierre, Lebrun, Christine, Cohen, Mikael, Ruet, Aurélie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207788/ https://www.ncbi.nlm.nih.gov/pubmed/28045953 http://dx.doi.org/10.1371/journal.pone.0168834 |
Ejemplares similares
-
Deciphering Depressive Mood in Relapsing-Remitting and Progressive Multiple Sclerosis and Its Consequence on Quality of Life
por: Lamargue Hamel, Delphine, et al.
Publicado: (2015) -
Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
por: Brochet, Bruno, et al.
Publicado: (2022) -
Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021) -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021) -
Pattern separation performance is decreased in patients with early multiple sclerosis
por: Planche, Vincent, et al.
Publicado: (2017)